Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MK-0616 in Healthy and Statin-Treated Participants
NCT06655311Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing Enlicitide Chloride with Placebo (2 arms). Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) and Number of Participants Who Discontinue Study Treatment Due to an AE. Started Sep 2022; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06655311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655311.